西藏药业：ART001于去年分别获批中国和美国IND

Core Viewpoint - Tibet Pharmaceutical (600211) is advancing its research and development efforts, particularly focusing on innovative treatments for specific medical conditions, including ATTR and familial hypercholesterolemia [1] Group 1: Product Development - The main product under development by Ruizheng Gene is ART001, targeting transthyretin amyloidosis (ATTR), which received IND approval in both China and the United States last year and is currently undergoing Phase I/IIa clinical trials in China [1] - Another product, ART002, is aimed at PCSK9 and is currently in an investigator-initiated trial (IIT) for familial hypercholesterolemia, although it has not yet obtained clinical approval [1] Group 2: Research and Development Investment - The company plans to adjust its future R&D expenditure based on the progress of its ongoing research projects [1]